Advanced search
Publication Cover
Expert Review of Vaccines Volume 7, 2008 - Issue 7
Submit an article Journal homepage
197
Views
57
CrossRef citations to date
0
Altmetric
Special Focus Issue: Cancer Vaccines - Review

Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation

Ayesha Murshid Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. [email protected]
,
Jianlin Gong Department of Medicine, Boston University Medical Center, Boston MA 02118, USA. [email protected]
&
Stuart K Calderwood Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. [email protected]
Pages 1019-1030 | Published online: 09 Jan 2014

References

  • Lindquist S, Craig EA. The heat shock proteins. Ann. Rev. Genet.22, 631–637 (1988).
  • Wegele H, Muller L, Buchner J. Hsp70 and Hsp90 – a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol.151, 1–44 (2004).
  • Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell. Biol.5, 781–791 (2004).
  • Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature40, 551–555 (2006).
  • Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci.62, 670–684 (2005).
  • Spiess C, Meyer AS, Reissmann S, Frydman J. Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. Trends Cell Biol.14, 14598–14604 (2004).
  • Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. Trends Biochem. Sci.33, 71–79 (2008).
  • Calderwood SK, Theriault JR, Gong J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur. J. Immunol.35, 2518–2527 (2005).
  • Srivastava PK. Heat shock protein-based novel immunotherapies. Drug News Perspect13, 517–522 (2000).
  • Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol.6, 593–599 (2005).
  • Tang D, Khaleque MA, Jones EL et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones10, 46–58 (2005).
  • Srivastava P. Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun.3, 3 (2003).
  • Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med.6, 435–442 (2000).
  • Asea A, Rehli M, Kabingu E et al. Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR)2 and TLR4. J. Biol. Chem.277, 15028–15034 (2002).
  • Vabulas RM, Ahmad-Nejad P, Ghose S et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem.277, 15107–15112 (2002).
  • Vabulas RM, Wagner H. Toll-like receptor-dependent activation of antigen presenting cells by Hsp60, Gp96 and Hsp70. In: Molecular Chaperones and Cell Signalling. B Henderson, AG Pockley (Eds). Cambridge University Press, Cambridge, UK 113–133 (2005).
  • Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol. Today13, 173–179 (1992).
  • Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell76, 287–299 (1994).
  • Udono H, Srivastava, PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med.178, 1391–1396 (1993).
  • Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol.20, 395–425 (2002).
  • Srivastava PK. Therapeutic cancer vaccines. Curr. Opin. Immunol.18, 201–205 (2006).
  • Binder RJ, Kelly JB 3rd, Vatner RE, Srivastava PK. Specific immunogenicity of heat shock protein Gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J. Immunol.179, 7254–7261 (2007).
  • Flechtner JB, Cohane KP, Mehta S et al. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. J. Immunol.177, 1017–1027 (2006).
  • Kunisawa J, Shastri N. Hsp90α chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity24, 523–534 (2006).
  • Enomoto Y, Bharti A, Khaleque AA et al. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell–tumor fusion cells. J. Immunol.177, 5946–5955 (2006).
  • Noessner E, Gastpar R, Milani V et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J. Immunol.169, 5424–5432 (2002).
  • Berwin B, Hart JP, Rice S et al. Scavenger receptor-A mediates Gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J.22, 6127–6136 (2003).
  • Doody AD, Kovalchin JT, Mihalyo, MA et al. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J. Immunol.172, 6087–6092 (2004).
  • Singh-Jasuja H, Scherer HU, Hilf N et al. The heat shock protein Gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol.30, 2211–2215 (2000).
  • Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members of the Hsp70 superfamily, bind to scavenger receptor-A and scavenger receptor expressed by endothelial cells-I. Eur. J. Immunol.37, 2268–2279 (2007).
  • Manjili MH, Park JE, Facciponte JG, Wang XY, Subjeck JR. Immunoadjuvant chaperone, GRP170, induces ‘danger signals’ upon interaction with dendritic cells. Immunol. Cell Biol.84, 203–208 (2006).
  • Villadangos JA, Heath WR. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol.17, 262–272 (2005).
  • Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol.7, 543–555 (2007).
  • Calderwood SK. Heat shock proteins in extracellular signaling. Methods43, 167 (2007).
  • Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins Gp96, Hsp90, Hsp70, and calreticulin. Immunity14, 303–313 (2001).
  • Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70–peptide complexes. J. Cell. Biol.158, 1277–1285 (2002).
  • Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity17, 353–362 (2002).
  • Calderwood SK, Theriault J, Gray PJ, Gong J. Cell surface receptors for molecular chaperones. Methods43, 199–206 (2007).
  • Theriault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK. Extracellular Hsp70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett.579, 1951–1960 (2005).
  • Theriault JR, Adachi H, Calderwood SK. Role of scavenger receptors in the binding and internalization of heat shock protein 70. J. Immunol.177, 8604–8611 (2006).
  • Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods43, 207–217 (2007).
  • Schnorrer P, Behrens GM, Wilson NS et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad. Sci. USA103, 10729–10734 (2006).
  • Cheng CF, Fan J, Fedesco M et al. Transforming growth factor α (TGFα)-stimulated secretion of Hsp90α: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFβ-rich environment during wound healing. Mol. Cell. Biol.28, 3344–3358 (2008).
  • Ramanayake T, Maniero GD, Morales H, Chida AS. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J. Immunol.180, 3176–3182 (2008).
  • Millar DG, Garza KM Odermatt B et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med.9, 1469–1476 (2003).
  • Vabulas RM, Ahmad-Nejad P, da Costa C et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem.276, 31332–31339 (2001).
  • Habich C, Kempe K, van der Zee R et al. Heat shock protein 60: specific binding of lipopolysaccharide. J. Immunol.174, 1298–1305 (2005).
  • Pido-Lopez J, Whittall T, Wang Y et al. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HspP70 up-regulates APOBEC3G expression in CD4+ T cells and dendritic cells. J. Immunol.178, 1671–1679 (2007).
  • Wang Y, Kelly CG, Karttunen JT et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity15, 971–983 (2001).
  • Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA. Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res.67, 4996–5002 (2007).
  • Kurotaki T, Tamura Y, Ueda G et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J. Immunol.179, 1803–1813 (2007).
  • Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr. Opin. Immunol.20, 89–95 (2008).
  • Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol.9, 558–566 (2008).
  • Bendz H, Ruhland SC, Pandya MJ et al. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J. Biol. Chem.281, 31688–31702 (2007).
  • Tamura Y, Kutomi G, Oura J, Torigoe T, Sato N. Piloting of exogenous antigen into cross-presentation pathway. In: Heat Shock Proteins in Cancer. Calderwood SK, Sherman MY, Ciocca DR (Eds). Springer, Dordrecht, ND, USA 383–396 (2007).
  • Kunisawa J, Shastri N. The group II chaperonin TRiC protects proteolytic intermediates from degradation in the MHC class I antigen processing pathway. Mol. Cell12, 565–576 (2003).
  • Castellino F, Boucher PE, Eichelberg K et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med.191, 1957–1964 (2000).
  • Haug M, Dannecker L, Schepp CP et al. The heat shock protein Hsp70 enhances antigen-specific proliferation of human CD4+ memory T cells. Eur. J. Immunol.35, 3163–3172 (2005).
  • SenGupta D, Norris PJ, Suscovich TJ et al. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J. Immunol.173, 1987–1993 (2004).
  • Asea A. Heat shock proteins and Toll-like receptors. Handb. Exp. Pharmacol.111–127 (2008).
  • Ohashi PS, DeFranco AL. Making and breaking tolerance. Curr. Opin. Immunol.14, 744–759 (2002).
  • Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev.199, 227–250 (2004).
  • Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-κB subunits. Immunity16, 257–270 (2002).
  • Cominacini L, Pasini AF, Garbin U et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-κB through an increased production of intracellular reactive oxygen species. J. Biol. Chem.275, 12633–12638 (2000).
  • Pan PY, Gu P, Li Q et al. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J. Immunol.172, 4779–4789 (2004).
  • Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem.278(42), 41173–41181 (2003).
  • Elsner L, Muppala V, Gehrmann M et al. The heat shock protein Hsp70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol.179, 5523–5533 (2007).
  • Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol. Chem.384, 267–279 (2003).
  • Massa C, Melani C, Colombo MP. Chaperon and adjuvant activity of Hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res.65, 7942–7949 (2005).
  • Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein Gp96–peptide complexes: clinical and immunologic findings. J. Clin. Oncol.20, 4169–4180 (2002).
  • Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res.9, 3235–3245 (2003).
  • Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol.178, 1975–1979 (2007).
  • Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science278, 117–120 (1997).
  • Yedavelli SP, Guo L, Daou ME et al. Preventive and therapeutic effect of tumor derived heat shock protein, Gp96, in an experimental prostate cancer model. Int. J. Mol. Med.4, 243–248 (1999).
  • Testori A, Richards J, Whitman E et al. Phase III comparison of Vitespen, an autologous tumor-derived heat shock protein Gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100–21 study group. J. Clin. Oncol.26, 955–962 (2008).
  • Melief CJ, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer8, 351–360 (2008).
  • Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol. Immunother.55, 329–338 (2006).
  • Rivoltini L, Castelli C, Carrabba M et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J. Immunol.171, 3467–3474 (2003).
  • Wang XY, Chen X, Manjili MH et al. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen Gp100. Cancer Res.63, 2553–2560 (2003).
  • Suzue K, Young RA. Adjuvant-free Hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol.156, 873–879 (1996).
  • Liu B, Ye D, Song X et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine26, 1387–1396 (2008).
  • Susumu S, Nagata Y, Ito S et al. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci.99, 107–112 (2008).
  • Mizukami S, Kajiwara C, Ishikawa H et al. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Cancer Sci.99, 1008–1015 (2008).
  • Calderwood SK. Chaperones and slow death – a recipe for tumor immunotherapy. Trends Biotechnol23, 57–59 (2005).
  • Daniels GA, Sanchez-Perez L, Diaz RM et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol.22, 1125–1132 (2004).
  • Melcher A, Murphy S, Vile R. Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Hum. Gene Ther.10, 1431–1442 (1999).
  • Kottke T, Sanchez-Perez L, Diaz RM et al. Induction of Hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res.67, 11970–11979 (2007).
  • Multhoff G. Activation of natural killer cells by heat shock protein 70. Int. J. Hyperthermia18, 576–585 (2002).
  • Multhoff G, Hightower LE. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones1, 167–176 (1996).
  • Krause SW, Gastpar R, Andreesen R et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical Phase I trial. Clin. Cancer Res.10, 3699–3707 (2004).
  • Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Naure Medicine10, 909–915 (2004).
  • Rosenberg SA. Shedding light on tumor immunotherapy of cancer. NEJM350, 1461–1463 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.